HMOX1 and silicosis: As a therapeutic strategy, HO-1 induction in pulmonary disease has been investigated for lipopolysaccharide-induced acute lung injury, influenza virus infection, bleomycin-induced pulmonary fibrosis, and silicosis [21,46,47,48].